Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia 3Neoplasms 2Melanoma 2Burkitt Lymphoma 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Philadelphia Chromosome 1Neoplasm, Residual 1Myeloproliferative Disorders 1Lymphangioleiomyomatosis 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hypereosinophilic Syndrome 1Hematologic Diseases 1Head and Neck Neoplasms 1Graft vs Host Disease 1Digestive System Neoplasms 1Desmoid Tumors 1Dermatofibrosarcoma 1Congenital Bone Marrow Failure Syndromes 1Chordoma 1Carcinoma, Adenoid Cystic 1

Interventions

nilotinib 2asciminib 2Dasatinib 2Cyclophosphamide 2fludarabine 1bosutinib 1Vincristine 1Prednisone 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Imatinib Mesylate 1Etoposide 1Dexamethasone 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Imatinib Mesylate × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡